5-2019

Letter to the Editor: Ketamine for pain management: Let’s not neglect practical concerns

Steven P. Cohen
Johns Hopkins School of Medicine; Uniformed Services University of the Health Sciences

Eric S. Schwenk
Thomas Jefferson University, eric.schwenk@jefferson.edu

Eugene R. Viscusi
Thomas Jefferson University, Eugene.Viscusi@jefferson.edu

Let us know how access to this document benefits you

Follow this and additional works at: https://jdc.jefferson.edu/anfp

Part of the Anesthesiology Commons

Recommended Citation
https://jdc.jefferson.edu/anfp/51

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Anesthesiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Letter to the Editor: Ketamine for pain management: let’s not neglect practical concerns

Steven P. Cohen¹,², Eric S. Schwenk³, Eugene R. Viscusi⁴, on behalf of the American Society of Regional Anesthesia & Pain Medicine and American Academy of Pain Medicine Ketamine Guidelines Committees

We read with interest the recent article on ketamine by Bell and Kalso.¹ In recent years, the use of ketamine to treat chronic pain and depression has exploded, and this article represents an easy-to-follow overview of this often misunderstood medication.

In their article, the authors focus on systematic reviews to draw broad conclusions on acute and chronic pain, without delving into the specifics of studies, including selection criteria and limitations. Although this methodology is sufficient for a topical review that summarizes basic information to include mainstream generalizations about efficacy and side effects, it is not capable of providing clinicians with practical recommendations that can be used to guide care such as indications and contraindications, dose regimens, benefit as an adjunct to opioids for acute pain, evidence for follow-up therapy with oral ketamine and other N-methyl-D-aspartate antagonists, how often and in whom to repeat procedures, how to prevent and treat adverse effects, and practical concerns such as how and by whom these patients should be monitored.

For both acute and chronic pain, this information and more is provided in recent guidelines along with a narrative review developed in a joint effort by the American Society of Regional Anesthesia & Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.²,³ Considering that anesthesiologists (not to mention other clinicians) comprise a plurality of International Association for the Study of Pain membership, these pragmatic concerns have clinical relevance for the Journal’s readership. We assume the time frame of this publication, which was revised and accepted in June 2018, prevented the inclusion of these guidelines, but would encourage readers interested in the practical elements of intravenous ketamine use for pain treatment to explore these resources.

Disclosures

The authors have no conflict of interest to declare.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

Acknowledgements

All authors served on the ASRA, AAPM, and ASA acute and chronic pain management ketamine guidelines committee, and Dr Schwenk is preparing an NIH grant evaluating ketamine for submission, but they report no conflicts related to this letter.

Article history:
Received 15 January 2019
Accepted 30 January 2019

References